Clinical Trials Logo

Stomach Neoplasms clinical trials

View clinical trials related to Stomach Neoplasms.

Filter by:

NCT ID: NCT05769725 Recruiting - Clinical trials for Serplulimab,Gastric Cancer, Adjuvant Therapy

A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of Serplulimab in Combination With Docetaxel +S-1 vs. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer (PD-L1 + / MSI-H / EBV +/dMMR) . Secondary study objective: To observe and evaluate the overall survival and adverse events of Serplulimab in Combination With Docetaxel +S-1 vs. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer (PD-L1+ / MSI-H / EBV +/dMMR). To evaluate the safety of Serplulimab in Combination With Docetaxel +S-1 vs. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer (PD-L1 + / MSI-H / EBV +/dMMR). To explore the incidence of PD-L1 + / MSI-H / EBV + /dMMR in stage IIIc gastric cancer. To explore the correlation of PD-L1 + / MSI-H / EBV + /dMMR in stage IIIc gastric cancer.

NCT ID: NCT05752357 Recruiting - Carcinoma Clinical Trials

The Role of Pre-operative and Post-operative Circulating Tumor Cells in Gastric Cancer.

Start date: September 1, 2021
Phase:
Study type: Observational [Patient Registry]

In resectable gastric cancer participants who received curative surgery, to early and more accurately detect peritoneal carcinomatosis or occult metastasis is important. Also, investigators will look at CTC numbers in different timings after operation, to investigate the possibility of early detection for peritoneal carcinomatosis or occult metastasis. Also, this study will correlate the relationship of CTC and participants' survival.

NCT ID: NCT05750290 Recruiting - Gastric Cancer Clinical Trials

CKD-702 Plus Irinotecan in Gastric Cancer

Start date: December 1, 2022
Phase: Phase 2
Study type: Interventional

CKD-702 is a tetravalent bispecific IgG1 targeting hepatocyte growth factor receptor (MET) and epidermal growth factor receptor (EGFR). The investigators will test a hypothesis that CKD-702 may augment the efficacy of biweekly irinotecan as a 3L or later therapy for gastric cancer overexpressing either MET or EGFR.

NCT ID: NCT05739045 Recruiting - Gastric Cancer Clinical Trials

Nivolumab Combined With SOX Used in the Perioperative Treatment

Start date: November 3, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the pathological complete response rate (pCR) of nivolumab combined with SOX (oxaliplatin + S-1) for neoadjuvant therapy of resectable gastric and gastroesophageal junction adenocarcinoma;

NCT ID: NCT05728606 Recruiting - Gastric Cancer Clinical Trials

Robot-assisted D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers

Start date: January 20, 2023
Phase: N/A
Study type: Interventional

To evaluate the safety of robot-assisted radical gastrectomy with D2 lymph node dissection in postoperative complications in patients with neoadjuvant chemotherapy for gastric cancer (cT3-4a, N+, M0).

NCT ID: NCT05723718 Recruiting - Gastric Cancer Clinical Trials

MalnutritiOn Assessment With biOelectrical impedaNce Analysis in gastRic Cancer patIentS Undergoing Multimodal trEatment

MOONRISE
Start date: December 20, 2022
Phase:
Study type: Observational

The aim of this single-arm prospective, multicenter, cross-sectional study is to evaluate the nutritional status and body composition on tumor regression grade with bioelectrical impedance analysis in gastric cancer patients undergoing multimodal treatment. Results of this study will reveal whether nutritional status and body composition assessment based on bioelectrical impedance analysis will become a validated and objective tool to support clinical decisions in gastric cancer patients undergoing multimodal treatment.

NCT ID: NCT05722275 Recruiting - Gastric Cancer Clinical Trials

Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics

Start date: January 1, 2023
Phase:
Study type: Observational

Peritoneal metastasis of gastric cancer is difficult to be detected in time, thus delaying treatment. Based on the conventional CT images of gastric cancer, this study plans to develop, improve and validate an intelligent analysis system based on radiomics. By extracting and combining the radiomics features related to peritoneal metastasis of gastric cancer, the intelligent analysis system could predict the risk of peritoneal metastasis, and provide personalized decision suggestions for the treatment of gastric cancer.

NCT ID: NCT05721651 Recruiting - Gastric Cancer Clinical Trials

Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study

Start date: April 2023
Phase: Phase 2
Study type: Interventional

Maintenance therapy is very important in advanced HER-2 negative gastric cancer, and immune monotherapy has no obvious benefit in the first-line maintenance treatment of advanced gastric cancer; Fruquintinib is a potent small-molecule VEGFR inhibitor with high kinase selectivity;Studies have shown that immunotherapy combined with antiangiogenic agents is promising for synergistic antitumor effects; The aim of this study was to observe and evaluate the efficacy and safety of Fruquintinib combined with PD-1 inhibitor in the first-line maintenance treatment of advanced HER-2 negative gastric cancer.

NCT ID: NCT05720598 Recruiting - Gastric Cancer Clinical Trials

Staging LaParoscopy to Assess Lymph NOde InvoLvement in Advanced GAstric Cancer

POLA
Start date: November 4, 2022
Phase: N/A
Study type: Interventional

Staging LaParscopy to Assess Lymph NOde InvoLvement in Advanced GAstric Cancer (POLA) study aims to investigate the safety and feasibility of ICG-guided SN retrieval in GC patients undergoing multimodal treatment. The pretreatment clinical variables potentially associated with the procedure will also be analyzed. To the best of our knowledge, the current study is the first to evaluate the role of ICG in SN biopsy in advanced GC patients undergoing multimodal treatment.

NCT ID: NCT05715632 Recruiting - Gastric Cancer Clinical Trials

New Adjuvant Treatment of Locally Advanced Resectable Gastric Cancer With Carelizumab and XELOX

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

To evaluate the efficacy and safety of carelizumab combined with XELOX regimen in neoadjuvant treatment of locally advanced resectable gastric cancer